SG10201701547VA - Water soluble membrane proteins and methods for the preparation and use thereof - Google Patents

Water soluble membrane proteins and methods for the preparation and use thereof

Info

Publication number
SG10201701547VA
SG10201701547VA SG10201701547VA SG10201701547VA SG10201701547VA SG 10201701547V A SG10201701547V A SG 10201701547VA SG 10201701547V A SG10201701547V A SG 10201701547VA SG 10201701547V A SG10201701547V A SG 10201701547VA SG 10201701547V A SG10201701547V A SG 10201701547VA
Authority
SG
Singapore
Prior art keywords
preparation
methods
water soluble
membrane proteins
soluble membrane
Prior art date
Application number
SG10201701547VA
Inventor
Shuguang Zhang
Alexander Rich
Karolina Corin
Lotta T Tegler
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of SG10201701547VA publication Critical patent/SG10201701547VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG10201701547VA 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof SG10201701547VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23

Publications (1)

Publication Number Publication Date
SG10201701547VA true SG10201701547VA (en) 2017-03-30

Family

ID=46721234

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201701547VA SG10201701547VA (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof
SG2013059811A SG192646A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013059811A SG192646A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Country Status (14)

Country Link
US (4) US8637452B2 (en)
EP (1) EP2709647B1 (en)
JP (1) JP6263773B2 (en)
KR (1) KR101963914B1 (en)
CN (2) CN103458915A (en)
AU (3) AU2012220558A1 (en)
BR (1) BR112013020969A2 (en)
CA (1) CA2827187C (en)
CL (1) CL2013002419A1 (en)
EA (1) EA201391041A1 (en)
IL (2) IL227886A0 (en)
MX (1) MX347038B (en)
SG (2) SG10201701547VA (en)
WO (1) WO2012116203A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6263773B2 (en) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー Water-soluble membrane proteins and methods for their preparation and use
CN105228592A (en) 2013-03-14 2016-01-06 麻省理工学院 For the multilamellar injectable self-assembling peptides scaffold hydrogel of long-time sustained release human antibodies
WO2014176524A2 (en) 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
US9670264B2 (en) * 2013-04-25 2017-06-06 The Trustees Of The University Of Pennsylvania Water soluble G-protein coupled receptor
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015148820A1 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
GB2527286A (en) 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
CN104198689A (en) * 2014-08-25 2014-12-10 李洁 Method for detecting response of G protein-coupled receptor to vaso-excitor material
CN106459174B (en) * 2015-02-18 2021-08-27 麻省理工学院 Water-soluble transmembrane proteins and methods of making and using same
CN104946674B (en) * 2015-06-17 2018-05-01 山东大学 A kind of adenosine triphosphate/bisphosphatase and its encoding gene and application
CN106749602A (en) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 It is a kind of to help expressed sequence and its application in acellular expression ADCY2 albumen
US11293923B2 (en) 2017-09-01 2022-04-05 Massachusetts Institute Of Technology S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof
CN111448320B (en) * 2017-12-11 2024-03-15 安斯泰来制药株式会社 Cell membrane penetrating peptide
CN108245686B (en) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 The purposes of people's GRK5 gene
US11555060B2 (en) * 2020-03-25 2023-01-17 Avalon GloboCare Corp. QTY FC fusion water soluble receptor proteins
WO2021202186A2 (en) 2020-03-31 2021-10-07 Massachusetts Institute Of Technology Qty fc fusion receptor proteins
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
NZ260103A (en) 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
JPH09278793A (en) * 1996-04-10 1997-10-28 Kinichiro Miura Polypeptide
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
JP2002539136A (en) * 1999-03-11 2002-11-19 グリフォン サイエンシーズ Chemical synthesis and use of soluble membrane protein receptor domains
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
WO2004065363A2 (en) 2003-01-21 2004-08-05 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
DE102004033902A1 (en) * 2004-07-14 2006-02-16 Zentaris Gmbh New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease
WO2006026355A2 (en) 2004-08-25 2006-03-09 Janssen Pharmaceutica N.V. Relaxin-chimeric polypeptides and their preparation and use
CN101137668B (en) * 2005-02-08 2011-08-17 研究发展基金会 Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
BRPI0502759B1 (en) * 2005-06-30 2014-02-25 lubricating oil and lubricating composition for a cooling machine
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
AU2007257936B2 (en) 2006-06-09 2011-05-26 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2008114020A2 (en) 2007-03-22 2008-09-25 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
US20100249022A1 (en) 2007-05-18 2010-09-30 University Of Massachusetts Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
DE08718604T1 (en) 2008-03-05 2009-12-24 Medical Research Council crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP6263773B2 (en) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー Water-soluble membrane proteins and methods for their preparation and use
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof

Also Published As

Publication number Publication date
US20160264640A1 (en) 2016-09-15
KR101963914B1 (en) 2019-03-29
KR20140027117A (en) 2014-03-06
JP6263773B2 (en) 2018-01-24
BR112013020969A2 (en) 2018-07-10
SG192646A1 (en) 2013-09-30
MX2013009715A (en) 2014-02-28
US9309302B2 (en) 2016-04-12
US8637452B2 (en) 2014-01-28
JP2014508763A (en) 2014-04-10
US20120252719A1 (en) 2012-10-04
CL2013002419A1 (en) 2014-06-06
EP2709647B1 (en) 2019-08-07
AU2017261525A1 (en) 2017-12-07
US10035837B2 (en) 2018-07-31
US20180312562A1 (en) 2018-11-01
CA2827187A1 (en) 2012-08-30
EA201391041A1 (en) 2014-04-30
CN103458915A (en) 2013-12-18
AU2012220558A1 (en) 2013-08-22
IL261151A (en) 2018-10-31
AU2016201914A1 (en) 2016-04-21
WO2012116203A1 (en) 2012-08-30
MX347038B (en) 2017-04-10
CA2827187C (en) 2019-01-08
EP2709647A1 (en) 2014-03-26
US20140243277A1 (en) 2014-08-28
IL227886A0 (en) 2013-09-30
CN108752461A (en) 2018-11-06
EP2709647A4 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
IL261151A (en) Water soluble membrane proteins and methods for the prepartion and use thereof
SG184289A1 (en) Novel peptides and methods for their preparation and use
EP2731998A4 (en) Modified sulfonated block copolymers and the preparation thereof
PL2675280T3 (en) Cheese and preparing the same
ZA201400562B (en) Axmi205 variant proteins and methods for their use
SG10201604332XA (en) Membrane and method for making the same
HK1251596A1 (en) Process for making polyarylethers and use in membrane preparation
PL2724117T3 (en) Inflatable membrane for use in three-dimensional imaging
IL231091A0 (en) Systems and methods for water desalinization
EP2627428A4 (en) Large volume disposable ultrafiltration systems and methods
ZA201406382B (en) Levoisovalerylspiramycin i,ii,iii and preparations ,preparation methods and uses thereof
EP2711376A4 (en) Fgfr-fc fusion protein and use thereof
HK1200340A1 (en) Dyes for membranes and biological structures
ZA201305266B (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EP2525900A4 (en) Nitrogen-permeable membranes and uses thereof
EP2752419A4 (en) Spirobenzylamine-phosphine, preparation method therefor and use thereof
EP2666831A4 (en) Waterproof pigment, preparing method and use thereof
EP2671572A4 (en) Patch and patch preparation
EP2671573A4 (en) Patch and patch preparation
EP2736369A4 (en) System and methods for connecting tissue patches
GB201005787D0 (en) Ultrasonic membrane
IL223436A (en) Methods for preparing tetranor-pgdm and tetranor-pgjm
AU2011904260A0 (en) Apparatus for use in the Harvesting of Tea
GB201010210D0 (en) Membrane preparation
PL396007A1 (en) Ionic liquids hexahydrothymol derivatives and process for the preparation of ionic liquids hexahydrothymol derivatives